Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AGIO
- Price
- 26.70
- Stock movement up
- +1.39 (5.49%)
- Company name
- Agios Pharm
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.52B
- Ent value
- 1.43B
- Price/Sales
- 46.32
- Price/Book
- 0.94
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 2.26
- Forward P/E
- -
- PEG
- -
- EPS growth
- 0.98%
- 1 year return
- -10.82%
- 3 year return
- -3.78%
- 5 year return
- -6.90%
- 10 year return
- -11.90%
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AGIO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 2.26 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 46.32 |
| Price to Book | 0.94 |
| EV to Sales | 43.63 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 57.03M |
| EPS (TTM) | 11.54 |
| FCF per share (TTM) | -5.65 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 32.87M |
| Gross profit (TTM) | 25.04M |
| Operating income (TTM) | -406.98M |
| Net income (TTM) | 674.31M |
| EPS (TTM) | 11.54 |
| EPS (1y forward) | -5.69 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 76.16% |
| Operating margin (TTM) | -1238.10% |
| Profit margin (TTM) | 2051.38% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 253.73M |
| Net receivables | 3.12M |
| Total current assets | 1.07B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 57.66M |
| Total assets | 1.79B |
| Accounts payable | 17.14M |
| Short/Current long term debt | 60.83M |
| Total current liabilities | 119.45M |
| Total liabilities | 165.12M |
| Shareholder's equity | 1.63B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -329.16M |
| Capital expenditures (TTM) | 952.00K |
| Free cash flow (TTM) | -330.11M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 41.45% |
| Return on Assets | 37.63% |
| Return on Invested Capital | 41.04% |
| Cash Return on Invested Capital | -20.09% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 25.52 |
| Daily high | 26.92 |
| Daily low | 25.00 |
| Daily Volume | 592K |
| All-time high | 135.01 |
| 1y analyst estimate | 56.50 |
| Beta | 0.75 |
| EPS (TTM) | 11.54 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 30 Apr 2025 |
Downside potential
Loading...
Downside potential data
| AGIO | S&P500 | |
| Current price drop from All-time high | -80.22% | -12.89% |
| Highest price drop | -87.36% | -56.47% |
| Date of highest drop | 14 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -57.15% | -11.07% |
| Avg time to new high | 63 days | 12 days |
| Max time to new high | 2577 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.52B
Marketcap category
Small-cap
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Employees
383
Website
Investor relations
-
SEC filings
CEO
Jacqualyn A. Fouse
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page